/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
With a market cap of $77.3 billion, Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company dedicated to discovering, developing, and commercializing innovative treatments for a wide range of serious medical conditions. With a strong portfolio of therapies addressing diseases such as eye disorders, allergic and inflammatory conditions, infectious diseases, cancer, and cardiovascular issues, it leverages cutting-edge science to improve patient outcomes. The Tarrytown, New York-based company is expected to unveil its fiscal Q4 earnings results before the market opens on Tuesday, Feb. 4.
Ahead of the event, analysts forecast the biopharmaceutical company to post a profit of $9.57 per share, reflecting a decrease of nearly 6% from $10.18 per share in the same quarter last year. The company has exceeded Wall Street's bottom-line projections in three of the past four quarters while missing on another occasion. REGN surpassed the consensus EPS estimate by a margin of 16.6% in the last reported quarter.
For fiscal 2024, analysts expect REGN to report EPS of $37.72, a marginal increase from $37.66 in fiscal 2023. Looking forward to fiscal 2025, its EPS is expected to grow 2.3% year-over-year to $38.57.
REGN has declined 25.1% over the past 52 weeks, underperforming the broader S&P 500 Index's ($SPX) 25.1% rise and the Health Care Select Sector SPDR Fund's (XLV) marginal gain over the same period.
Despite reporting better-than-expected Q3 adjusted EPS of $12.46 and revenue of $3.7 billion, shares of REGN tumbled 9.2% on Oct. 31 due to concerns over weaker-than-expected U.S. Eylea sales. Sales of Eylea, the company’s key product, declined 21% year-over-year, missing estimates as increased competition led to reduced volumes and pricing pressures. Additionally, Libtayo sales of $289 million, while up 24% year-over-year, missed expectations. Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns.
Analysts' consensus rating on Regeneron Pharmaceuticals stock is bullish, with a "Strong Buy" rating overall. Out of 26 analysts covering the stock, opinions include 19 "Strong Buys," one "Moderate Buy," five "Holds," and one "Moderate Sell." As of writing, REGN is trading below the average analyst price target of $1,061.84.
